Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is this the start of a raid?
I just have this feeling that there is something that will be presented that is new to us. I think the asgct is the one that none of us have figured out yet. Tomorrow will be interesting to find out.
You beat me to it. Thanks. Well, we will probably have a nice PR on Monday.
Is it the 26th? I was under the impression that it was today. I'm probably wrong. You are right that they can't present the same data but heller is also the combination anti pd-1 presenter. I'm hoping to see some data justification for the anti pd-1 trial.
In other words, no new data but maybe forecasts for the combo trial.
ASGCT abstract release today. Very curious. Does anyone know the exact time it is released today?
Yup. When it goes, it's going to really go. Can't wait.
Yah. I don't think the partner for neopulse is going to be the same partner for phase 2b. I have a feeling the neopulse will be a narrow partnership limited to just that and not a throw in piece with a larger partnership.
I think the main issue is how extensive a partnership is the partnership with the anti Pd-1 going to be. For example, if you are going to do a combo trial with anti pd-1 for melanoma, why wouldn't you start the phase 1 breast trial also using a combination approach? Make sense to me. If il-12 turns non-responders into responders then that wouldn't that apply to other types of tumors?
I think oncs wants a partner that will finance both it's melanoma and other solid tumor indications. I can just see it now: Ali Daud presenting data for combination trials at ASCO 2015. Of the charts!!!
That's a good point. So, you think its ONCS that is waiting? Interesting. That would follow the way they generally do things (get if right).
Also, do you think that Merck is waiting to see the results from the dosage change?
I know we have talked about all these issues to death, but just curious everyone's thoughts.
I tend to agree but I was just wondering if there were some rule or legal reason to not allow that to happen before ASCO. Thanks.
So, theoretically, Merck has been able to see this data since February (I say that because that is when they sent the data into ASCO)?
If that is true, partnership is very possible before ASCO, especially if they want to the the P2 trial going as soon as possible. Good times.
She is that.
I have a question for the group:
If Merck wanted to partner with ONCS (which we all know is likely), would they have access to P2 final data already or is that data exclusive to ASCO?
It seems that if they haven't viewed that data, then a partnership is not going to happen before ASCO. If they have, it could happen any day now.
Thoughts?
Totally agree lasers. Locked and loaded. I really think this is about to break out in a big way.
It certainly is, without all the negative side effects. You better get in quick, ONCS has had three consecutive PR's in a row. Going for #4 tomorrow with ASGCT abstract release Friday. Don't get yourself caught with your pants down Sal. :) LOL.
Either way, I'd take your own advise and get in. :). My thought process last week when I bought 40,000 more shares is that I'd harvest some of the long- term capital gains in September and have these the shares that I don't think about until next April. That way you get the max amount of tax benefit but keep the number of shares up until it gets really really valuable next year. I think 2015 is where oncs is either going to be $3-5 or higher or when they get acquired.
Tough call. I think either way, it would be a sound decision.
Also sal, Of you haven't done so skready, I've started the process of talking to my accountant about the tax aspect of selling. This is very important because for us longs that have been in since last fall, the aspects of the right business decision starts interacting with tax decisions. Of course, if you are using retirement accounts, that is not an issue. But, if you are like me, where it is in mostly cash accounts, it makes a big difference.
Great news today!!! Love the string of PR's.
Just a thought today: I have a feeling that this is going to break out really hard instead of the 8-10% gains per day like we saw in Dec and March. I think the MM's know this and shares are being loaded up cheap for a reason. When it runs, I think its going to run really hard. Like Twiz said earlier: looks like a volcano looking to erupt. Its going to be fun friends.
Check this out:
Super Stock Profits Top Five Small Cap Focus List: Onco Sec Medical, Inc. CannaVest Corp, AvWorks Aviation, MedBox, Inc. mCig, Inc.
BY PR Newswire
— 7:03 AM ET 04/23/2014
LONDON, April 23, 2014 /PRNewswire/ --
The volume picked up from the hangover of the long weekend in trading yesterday but still a way off the levels we witnessed over the last month. We expect that volume to pick up substantially as we move into earnings season and the last couple of months before the summer slowdown.
Onco Sec Medical continued to be tracked after the stock climbed up the volume charts in early trading on Tuesday in the markets. Shares in Onco Sec Medical were higher by more than 8% on $2.2 million in volume. With resistance around the $0.90 cent level it seems the company could be on the comeback trail.
CannaVest Corporation (CANV
Loading...
Loading...
) was back on the watch list today for the wrong reasons for once as it traded lower by 24% all be it on lighter volume. CannaVest remained one of the heaviest traded stocks within the OTC market in a strong trading day for the stock.
If you are looking to receive our latest weekly picks as well as the latest news and volume trades sent directly to your inbox we invite you to sign up directly at Super Stock Profits.
MedBox, Inc. (MDBX
Loading...
Loading...
) had a heavy days trading in a lightly traded market also with a close lower in the mid $23.00 range. The stock in similar fashion to CannVest has been the subject of much attention over the last few months climbing to more than $100 per share at one point. The volume was over $2.5 million but has been increased substantially over the last week as the stock has moved 30% since we last reported on Thursday of last week. We will continue to track shares which did pull back around 5% in today's action.
Avworks Aviation (SPLI
Loading...
Loading...
) was the heaviest traded stock on the board outside of Fannie Mae (FNMA
Loading...
Loading...
) trading just under $3 million with shares pulling back just a few percentage points today. The stock is looking to trade higher to the resistance point of last week and has most likely been the subject of profit taking.
mCig (MCIG
Loading...
Loading...
) was one of the green lights in a sea of red as that stock continued its charge towards $0.90 per share, closing just below $0.60 in a heavy traded day for the company. Shares were higher by 7% on more than $2.5 million traded.
Super Stock Profits releases our daily trading report of the top trading volume and percentage leader plays within the small cap markets, keeping you up to date with the latest picks and the latest news on the stocks in focus.
Disclosure: Super Stock Profits is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities but for informational purposes only. Investors should always conduct their own due diligence with any potential investment. Super Stock Profits is affiliated with AMG Global Advisors Ltd which is a FINRA registered company (168847). We have not been compensated by any of the companies listed in this news release
Contact: info@superstockprofits.com
Tel: +1-561-866-2256
Lol!! Right after I did that, I got notification from their new newsletter with all those links. Oh well.
By the way, it is obvious that ONCS is listening to investors concerning news and updates. I wrote them and said thanks for their efforts in fixing this problem. I encourage all of you to do the same.
1. Pegs: http://www.pegsummit.com/Cancer-Antibodies/
11:10 Glass Half-Empty or Half-Full? Potential Mechanisms of Non-Response to Immunomodulatory Antibodies
PiearceABCRobert H. Pierce, M.D., CMO, OncoSec Medical, Inc.
2. EADO: http://www.eado2014.com/user/_files/30/Program%202014-04-03.pdf
ImmunePulse phase II study
Axel Hauschild (Kiel, DE)
3. Boston Biotech Cancer Advance: http://bbbiotechconference.com/conference-agenda.php?id=23
4:40 PM-5:20 PM Cancer in 15 Years: Predictions
Punit Dhillon, OncoSec; Ferran Prat, MD Anderson Cancer Center; Robert Wild, Eli Lilly; Krishna Yeshwant, Google Ventures
Moderator: Ashley Dombkowski, Bay City Capital
4. ASGCT 17th Annual Meeting: http://asgct.execinc.com/edibo/AM14FullSchedule
Richard Heller, PhD
Non-Viral Gene Transfer of pIL-12 for the Treatment of Melanoma: Results from Phase I and II Clinical Trials
Electrotransfer of plasmids encoding cytokines directly to tumors has been shown to generate a local and systemic anti-tumor effect in both preclinical and clinical studies. In the clinical studies, patients with in-transit cutaneous melanoma received at least one treatment cycle (days 1, 5, 8) of intratumor pIL-12 delivered by electrotransfer in up to four lesions per cycle. In both the Phase I and II trials increases in IL-12 levels and enhanced immune activity were observed and the therapy was well tolerated. Intratumor treatment with pIL-12 electro transfer exhibited a systemic antitumor immune response with activity in both treated and non-treated sites of disease and objective response to treatment. These positive results provide the rationale for an expanded study.
5. ASCO 59th Annual Meeting: http://ir.stockpr.com/oncosec/company-news/detail/1344/oncosec-medical-selected-to-present-phase-ii-data-in-poster-highlights-session-at-2014-asco-annual-meeting
6. Marcum Conference: http://www.marcumllp.com/MicroCap/presenting-companies
The Marcum MicroCap Conference is dedicated to introducing investors to the very best, undiscovered companies under $500 million in market capitalization. Launched in 2012, the annual Marcum MicroCap Conference features presentations by CEOs and CFOs from promising high-growth companies, the top picks by some of the most astute analysts following small caps, and thoughtful commentary on successful investment strategies and sectors. Marcum is again partnering with KCSA Strategic Communications and Launchpad Investor Relations to host the conference in its third year.
This invitation-only event attracts top fund managers and qualified high net worth investors who focus on small cap equities. One-on-one meetings are available for company management teams and qualified investors.
7. ACS Blossom Ball: http://localwiki.net/yuba-sutter/American_Cancer_Society_Blossom_Ball
American Cancer Society Announces Blossom Ball Event, Sunset in the Buttes • May 31, 2014
The fifth annual American Cancer Society (ACS) Blossom Ball fundraiser is quickly becoming the most exciting and elegant event in our community. This year’s outdoor black-tie event will feature gourmet dining, live entertainment, dancing under the stars and an appealing array of items in both live and silent auctions. Last year’s successful inaugural event, which was attended by over 400 people, raised more than $105,000 for the fight against cancer.
This year’s Blossom Ball will be held on Saturday, May 31, from 6 pm until 12 midnight, at the Southridge Golf Club, 9413 South Butte Road, Sutter, California 95982. Tickets are $100 each, with proceeds going to support ACS programs, patient services and cancer research.
Oh, I agree to hold. Just surprised that the pr is not making it move more than it is.
Why is this going down on this PR? I don't get it.
Do you think that is part of why they hired her? It seems to me.
Jean Campbell is such a great hire for so many reasons. However, what struck me the most was that she is not an oncologist by an assistant professor/biochemist who runs a research lab. What was triggered in my mind was the BioCeo conference where one of the slides listed the broad applicability of ImmunoPulse that is BEYOND cancer to include all kinds of diseases where the delivery system of ImmunoPulse lowers toxicity and costs in other infectious diseases. Punit even mentioned this as a possible long term possibilities for ImmunoPulse. I believe (and I hope) we are seeing the first sign that ONCS is planning to go beyond cancer. I'm really curious what the rest of you think.
For example, they list three areas where they list the broad application in their Corporate presentation listed on their website (Descriptions are from Wikipedia). The basic jist is that there is a whole array of diseases that ImmunoPulse could help:
1. Proinflammatory Cytokine: a cytokine which promotes systemic inflammation. Due to their proinflammatory action, they tend to make a disease worse by producing fever, inflammation, tissue destruction, and, in some cases, even shock and death. Reducing the biological activities of proinflammatory cytokines can reduce the brunt of attack of diseases mediated by proinflammatory cytokines. Blocking IL-1 or TNF has been highly successful in patients with rheumatoid arthritis, inflammatory bowel disease, or graft-vs-host disease.
2. Immuno-modulator receptors: I can't quite figure this one out. If anyone can, please help.
3. Cell trafficking molecules: I can't quite figure this one out either. If anyone can, please help.
Attached is the link to the conference:
http://www.veracast.com/bio/ceoinvestor2014/main/events/1404_oncose/pdf/OncoSec_Medical.pdf
Below is a link to Jean Campbell's profile at University of Washington:
http://www.pathology.washington.edu/faculty/campbell
He was closest to the camera when talking about the cash position. Lol!
Good question/comment over on the yahoo board:
"There were two types of poster presentations, one that was just posters, one that was posters plus oral, the 2nd is what we got I'm sure, and honestly about what I expected us to get. ONCS would have to be in P3 to get one of the cool spots."
Can we tell what kind it is?
Totally agree. That's why I believe that your initial interpretation of a private placement in a partnership is the most logical interpretation. Monday morning might be a really good day.
But those are the trials that don't need much money. With orphan designation, those will be making money!! Neopulse could make money soon too.
I agree. I think that the consensus is that it may be a partnership or a public offering when the pps is higher. Either way, good stuff.
I agree. I do think your analysis of a private placement is correct. Punit was directly asked about funding at nedham and he specifically stated that their goal was to fund phase 2b through a partner. Further, when asked about the Merck partnership in his tv interview, he was almost giddy.
I understand jbeam77's perspective and his analysis is usually right for most s-3 filings in biotech. The only way his theory would seem correct is if they were planning to dilute AFTER a partnership was announced and all their current trial data was released. At that point, their pps would be really high and a dilution would make sense.
Either way though, this filing is extremely bullish and us shareholders are in for a very exciting ride coming as quick as Monday morning.
Actually, I missed the best day on Tuesday. I bought 40,000 shares between last Thursday and this Monday averaging .70. Oh well. Have no extra cash right now but am locked and loaded for the coming run.
Yup, exactly. I think it is more than "one." Also, I wouldn't be surprised if we see some SEC filings that show some huge holdings soon.
The release of the title of the ASCO abstract will tell us longs a lot. I expect that our pps will increase next week but not explode. For me, the title of the abstract will tell us what to expect at ASCO where the real fireworks will begin and a huge rise in pps will occur thereafter. For me, this coming Monday is kind of like last week where Punit spilled the beans about presenting at ASCO (we had waited a long time for even that news). Even though it didn't affect the pps (in fact went down slightly) it affect my investing decisions. I already owned 330,000 shares before that that I was not planning to sell until at least a year from purchase or longer. However, his announcement spurred me to find more money and play the ASCO data release on a short term basis as well while keeping my long term position in place.
All in all, I think most people here are excited to find out more pieces of the puzzle and that is very exciting. For example, as lasers pointed out, the same author can present two abstracts at ASCO. Could it be that the data is melanoma and Merkel cell or melanoma an cutaneous t-cell, or just melanoma alone, etc.? If the title has multiple data releases, this could further guide investment decisions. So, we will see.
I know, right? Can't wait.
Sometimes its good to go back to what a companies promises and what they deliver. Attached is the 2014 company strategy. I think they are doing quite well fulfilling their promises.
SAN DIEGO, CA, January 14, 2014 — OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced a strategic update and reported on progress made in 2013. Progress included advancing metastatic melanoma, Merkel cell clinical programs and preclinical combination studies with anti-PD-1, anti-PDL-1, and anti-CTLA4, which highlight a commercial path forward.
“2013 was a landmark year for OncoSec in which we earned recognition in both the scientific and investment communities as a fast-emerging leader in cancer immunotherapy,” said Punit Dhillon, OncoSec’s president and CEO. “Culminating a year of aggressive clinical development activity, the interim results of our Phase 2 melanoma study underscore the potential of ImmunoPulse to shift the treatment paradigm for patients with metastatic melanoma and generate significant value for stakeholders.”
“Having welcomed our CMO, Robert Pierce, M.D., former Merck Research Labs Executive Director/Member of Global anti-PD-1 Development Team to oversee OncoSec’s clinical development studies, we look forward to further advancing our melanoma program this year as we continue to progress and expand our other clinical and preclinical programs. With a solid balance sheet, a promising pipeline and enhanced R&D and manufacturing capabilities, we are entering 2014 well positioned to continue building on the meaningful progress we have made over the last year.”
The following is an overview of key strategic goals for OncoSec’s ImmunoPulse program in 2014:
Metastatic melanoma Phase 2 study (OMS-I100)
Complete enrollment in study being led by the University of California San Francisco (UCSF), University of Washington and other U.S. cancer centers
Evaluate dose-intensified treatment schedules
Report interim and final analysis of clinical data
Initiate Phase 2b metastatic melanoma study
Merkel cell carcinoma Phase 2 study (OMS-I110)
Complete enrollment in study being led by the University of Washington and UCSF
Report clinical data
Expand Phase 2 cutaneous T-cell lymphoma study to a multi-institution trial to enhance enrollment and leverage additional expertise in CTCL
Initiate additional Phase 1 study in new solid tumor indication
The following is a summary of milestones achieved in 2013 and additional detail on the company’s vision for 2014:
Metastatic melanoma Phase 2 study (OMS-I100)
Last December, interim data from OncoSec’s ongoing Phase 2 trial in metastatic melanoma confirmed the safety of ImmunoPulse; to date, a total of 47 melanoma patients have been treated without a single serious adverse event. In addition, patients demonstrated positive response rates, reinforcing the encouraging clinical results from the Phase 1 study.
Importantly, the data also indicated a systemic antitumor immune response in 61.1% of evaluable patients (11/18), as evidenced by objective regression (>30% reduction in size) in at least one untreated lesion. This finding, coupled with the favorable safety data, indicates the potential of ImmunoPulse to deliver systemic benefit, without the toxicities associated with many other systemic treatments.
Having completed enrollment of 25 patients, OncoSec expects to reach its expanded enrollment target of 30 patients in the near future and report additional data from the trial in mid 2014. As OncoSec prepares to initiate a potential Phase 2b study, the company is also planning to evaluate additional dose-intensified treatment schedules in the current trial and report interim and final analysis later this year.
Merkel cell carcinoma Phase 2 study (OMS-I110)
In partnership with leading clinical centers, OncoSec is continuing enrollment in a Phase 2, open-label, single-arm study in Merkel cell carcinoma. OncoSec expects to complete enrollment in this trial in the first quarter and report additional data from the trial in mid 2014.
Expansion of ImmunoPulse development programs
Last June, OncoSec entered into a sponsored research agreement with Old Dominion University to evaluate ImmunoPulse in combination with various therapeutic agents, including anti-CTLA4, anti-PD-1, anti-PD-L1 and other immune modulators. As OncoSec continues to investigate ImmunoPulse as monotherapy, this collaboration will enable the company to identify combination approaches that may enhance the efficacy of ImmunoPulse.
In 2014, OncoSec also expects to expand ImmunoPulse into at least one new solid tumor indication to increase its development pipeline.
Strategic growth opportunities
In 2013, OncoSec relocated to a new 6,000 sq. ft. facility where all research and development and general and administrative activities are managed, as well as in-house capabilities to build, maintain and develop its own devices. In 2014, the company expects to enhance manufacturing capabilities for ongoing and future clinical trials, through additional efficiencies and the ability to scale up production as needed to support potential partners.
Other key areas of growth this year will focus on technical operations, including:
Launching new applicator probes for clinical trials
Completing working prototype of new OMS Electroporation device
Renewing ISO13485 qualification and certification
Renewing CE Mark of OncoSec Medical System
Completing additional in-licensing opportunities
Expanding R&D footprint by acquiring or outsourcing additional lab facilities
OncoSec plans to hire additional scientists and engineers to support these goals. Next-generation devices and new DNA-based constructs resulting from these efforts are expected to build product value by generating additional intellectual property, both organically and through other in-licensing opportunities.
Business development
With a strong balance sheet of $15.2 million as of Q4 2013, OncoSec plans to continue focusing on advancing an aggressive clinical development strategy while maintaining its relatively lean burn rate.
The company continues to focus on clinical development opportunities, which includes potentially initiating proprietary programs funded by third parties. The company is actively seeking additional grant funding and strategic partnerships to further develop its novel immunotherapy products.
Dhillon stated, “OncoSec has made great progress in 2013 that has served to validate our clinical efforts and expand our visibility in the scientific community. We look forward to an excellent year ahead and will continue building on our strong fundamentals with the goal of increasing shareholder value, while delivering a meaningful benefit to patients and families impacted by cancer.”
Actually, I don't think that is a conspiracy theory at all but mostly based upon facts.
1. In Punit's interview in New York last week, the key statement was that they were planning on starting AT LEAST two other trials. Then he went onto emphasize breast and mentioned head and neck.
2. In Zoriden's interview with Punit--he specifically stated that they were looking into MULTIPLE partnerships. I know there has been a lot of talk about Neopulse being the throw in for a partnership with Big Pharma. I personally don't think that is how it will play out. I think there will be two partnerships that take place for several reasons. First, ONCS gets a better deal if there are two partnerships because whenever two things are put together, that combination almost always de-values one of them. Second, Punit knows the true value of both programs. Since they have already turned down offers for Neopulse, I truly think that he is waiting for the fair offer. In Zoriden's interview, he stated that those offers (and he said plural) were getting closely. Third, I believe Neopulse's value has gone up in the past few months with Europe's passing of accelerated approval. Punit specifically mentioned this in the tv interview last week. Therefore, if you can get the product to market quicker, the value goes up.
All in all, I truly believe that the pps predictions of $2-3 by the end of the year will be low. Can't wait.
Yes. That is good advice Wait. This is only frustrating aspect of ONCS. Their website sucks and I still can't figure out their PR. For example, the timelines under the investor tab don't match the timeline of events in another tab. It just appears tacky and lame. However, it probably won't matter really soon.
I really appreciate your DD on this board. Keep it up.
Yes. See the following link:
http://asgct.execinc.com/edibo/AM14FullSchedule
Click on #213. Dr. Heller's lecture is the second one down.
Thanks. I guess I didn't make it clear that I was specifically referring to ONCS and not the market as a whole.
Me too!!!